Chargement en cours...
How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
Recent claims that pioglitazone prevents macrovascular events are based on a secondary outcome measure. But ignoring the primary outcome is statistically unsound
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group Ltd.
2005
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1246089/ https://ncbi.nlm.nih.gov/pubmed/16210286 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|